Evaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad.

ilustraciones, diagramas

Autores:: Medina Parra, Jorge Alexis

Tipo de recurso:

Fecha de publicación:: 2022

Institución:: Universidad Nacional de Colombia

Repositorio:: Universidad Nacional de Colombia

Idioma:

id	UNACIONAL2_36f02bca4d29003182a00dce28f08f1d
oai_identifier_str	oai:repositorio.unal.edu.co:unal/84577
network_acronym_str	UNACIONAL2
network_name_str	Universidad Nacional de Colombia
repository_id_str
dc.title.spa.fl_str_mv	Evaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad.
dc.title.translated.eng.fl_str_mv	Economic evaluation of procalcitonin as a guide to antibiotic therapy for acute respiratory infection in adults in a reference hospital in Colombia 2019. Cost-effectiveness analysis.
title	Evaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad.
spellingShingle	Evaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad. 610 - Medicina y salud::616 - Enfermedades Costo d emedicamentos Fármacos del sistema respiratorio Drug Costs Respiratory System Agents Análisis de costos Cost analysis Procalcitonina Neumonía Costo Efectividad Evaluación de Tecnologías en Salud Infección Respiratoria Aguda Procalcitonin Pneumonia Cost Effectiveness Health Technology Assessment Acute Respiratory Infection
title_short	Evaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad.
title_full	Evaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad.
title_fullStr	Evaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad.
title_full_unstemmed	Evaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad.
title_sort	Evaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad.
dc.creator.fl_str_mv	Medina Parra, Jorge Alexis
dc.contributor.advisor.none.fl_str_mv	Gaitan Duarte, Hernando Guillermo
dc.contributor.author.none.fl_str_mv	Medina Parra, Jorge Alexis
dc.subject.ddc.spa.fl_str_mv	610 - Medicina y salud::616 - Enfermedades
topic	610 - Medicina y salud::616 - Enfermedades Costo d emedicamentos Fármacos del sistema respiratorio Drug Costs Respiratory System Agents Análisis de costos Cost analysis Procalcitonina Neumonía Costo Efectividad Evaluación de Tecnologías en Salud Infección Respiratoria Aguda Procalcitonin Pneumonia Cost Effectiveness Health Technology Assessment Acute Respiratory Infection
dc.subject.decs.spa.fl_str_mv	Costo d emedicamentos Fármacos del sistema respiratorio
dc.subject.decs.eng.fl_str_mv	Drug Costs Respiratory System Agents
dc.subject.lemb.spa.fl_str_mv	Análisis de costos
dc.subject.lemb.eng.fl_str_mv	Cost analysis
dc.subject.proposal.spa.fl_str_mv	Procalcitonina Neumonía Costo Efectividad Evaluación de Tecnologías en Salud Infección Respiratoria Aguda
dc.subject.proposal.eng.fl_str_mv	Procalcitonin Pneumonia Cost Effectiveness Health Technology Assessment Acute Respiratory Infection
description	ilustraciones, diagramas
publishDate	2022
dc.date.issued.none.fl_str_mv	2022
dc.date.accessioned.none.fl_str_mv	2023-08-17T14:28:52Z
dc.date.available.none.fl_str_mv	2023-08-17T14:28:52Z
dc.type.spa.fl_str_mv	Trabajo de grado - Maestría
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/masterThesis
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/acceptedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/TM
status_str	acceptedVersion
dc.identifier.uri.none.fl_str_mv	https://repositorio.unal.edu.co/handle/unal/84577
dc.identifier.instname.spa.fl_str_mv	Universidad Nacional de Colombia
dc.identifier.reponame.spa.fl_str_mv	Repositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourl.spa.fl_str_mv	https://repositorio.unal.edu.co/
url	https://repositorio.unal.edu.co/handle/unal/84577 https://repositorio.unal.edu.co/
identifier_str_mv	Universidad Nacional de Colombia Repositorio Institucional Universidad Nacional de Colombia
dc.relation.references.spa.fl_str_mv	Malo DC, Pulido PA. Infección Respiratoria Aguda Colombia 2017. Instituto Nacional de Salud 2018 Abril 20 de. World Health Organization. Pneumonia. 2021; Available at: https://www.who.int/news-room/fact-sheets/detail/pneumonia. Recomendaciones para el diagnóstico, tratamiento y prevención de la neumonía adquirida en la comunidad en adultos inmunocompetentes. Infectio 2013;17:1-38. DANE. Boletín Técnico Estadísticas Vitales. DANE 2016 30 de Marzo de. Montúfar FE, Rueda ZV, Correa LT, Ortega H, Ortega J, Segura A. Características y comportamiento de la Neumonía Adquirida en la Comunidad (NAC) en adultos mayores (≥ 65 años) hospitalizados en el Valle de Aburrá, Antioquia, Colombia. Infectio 2006(10):113. Hincapié C, Ascuntar J, León A, Jaimes F. Neumonía adquirida en la comunidad: comparación de tres puntuaciones de predicción de mortalidad en el servicio de urgencias. Colombia Médica 2021;52(4):e2044287. Fabian Bautista Peña. Perfil clínico, epidemiológico y microbiológico de los pacientes con neumonía en un hospital de Bogotá en el periodo de 2016-2019Universidad Nacional de Colombia; 2019. Pantoja-Chamorro F, Mazzillo-Vega L, Palacios-Barahona U. Análisis de la asociación entre procalcitonina y mortalidad por sepsis en menores de 18 años en una unidad de cuidados intensivos, Pasto-Colombia 2012-2014. Universidad y Salud 2018;20(1):64-71. González Rangel DM. Procalcitonina sérica como marcador de infección bacteriana comprobada por medio de cultivo en niños hospitalizados en la Fundación Hospital de la Misericordia (HOMI). Departamento de Pediatría 2014. Zaas AK, Garner BH, Tsalik EL, Burke T, Woods CW, Ginsburg GS. The current epidemiology and clinical decisions surrounding acute respiratory infections. Trends Mol Med 2014;20(10):579-588. Thapa S, Gokhale S, Sharma AL, Sapkota LB, Ansari S, Gautam R, et al. Burden of bacterial upper respiratory tract pathogens in school children of Nepal. BMJ open respiratory research 2017;4(1):e000203. Graham NM. The epidemiology of acute respiratory infections in children and adults: a global perspective. Epidemiol Rev 1990;12:149-178. Dasaraju PV, Liu C. Infections of the Respiratory System. 4th ed.: University of Texas Medical Branch at Galveston; 1996. Carroll KC, Adams LL. Lower Respiratory Tract Infections. Microbiol Spectr 2016 -08;4(4). Mahashur A. Management of lower respiratory tract infection in outpatient settings: Focus on clarithromycin. Lung India: Official Organ of Indian Chest Society 2018;35(2):143. Hopstaken RM. Lower respiratory tract infections unravelled. Ned Tijdschr Geneeskd 2019;163. Community-acquired pneumonia: the US perspective. Seminars in respiratory and critical care medicine: © Thieme Medical Publishers; 2009. Longo DL, Jameson JL, Kaspe D. Harrison's Principles of Internal Medicine: Volume 2. : Macgraw-Hill; 2011. Robinson NE, Furlow PW. Anatomy of the respiratory system. Equine respiratory medicine and surgery 2007:3-17. Robinson KM, Kolls JK, Alcorn JF. The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol 2015;34:59-67. Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. American journal of respiratory and critical care medicine 1999;160(2):397-405. Lower respiratory tract infection and pneumonia in the community. Seminars in respiratory infections; 1999. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia?: Diagnosing pneumonia by history and physical examination. JAMA 1997;278(17):1440-1445. Protocolo de Vigilancia en Salud Pública, Infección Respiratoria Aguda. Instituto Nacional de Salud. Equipo Imunoprevenibles 2017. Ilg A, Moskowitz A, Konanki V, Patel PV, Chase M, Grossestreuer AV, et al. Performance of the CURB-65 score in predicting critical care interventions in patients admitted with community-acquired pneumonia. Ann Emerg Med 2019;74(1):60-68. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243-250. Lim HF, Phua J, Mukhopadhyay A, Ngerng WJ, Chew MY, Sim TB, et al. IDSA/ATS minor criteria aid pre-intensive care unit resuscitation in severe community-acquired pneumonia. European Respiratory Journal 2014;43(3):852-862. Domínguez-Comesaña E, Ballinas-Miranda JR. Procalcitonin as a marker of intraabdominal infection. Cir Cir 2014;82(2):231-239. Henriquez-Camacho C, Losa J. Biomarkers for sepsis. BioMed research international 2014;2014. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. The Journal of Clinical Endocrinology & Metabolism 1994;79(6):1605-1608. Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med 2013;28(3):285. Adib M, Bakhshiani Z, Navaei F, Fosoul FS, Fouladi S, Kazemzadeh H. Procalcitonin: a reliable marker for the diagnosis of neonatal sepsis. Iranian journal of basic medical sciences 2012;15(2):777. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. The Lancet infectious diseases 2013;13(5):426-435. Wu M, Lin C, Huang S, Shih H, Wang C, Lee C, et al. Can procalcitonin tests aid in identifying bacterial infections associated with influenza pneumonia? A systematic review and meta‐analysis. Influenza and other respiratory viruses 2013;7(3):349-355. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. European Respiratory Review 2017;26(143). Schuetz P, Wirz Y, Sager R, Christ‐Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews 2017(10). Smith KJ, Wateska A, Nowalk MP, Raymund M, Lee BY, Zimmerman RK, et al. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. Journal of general internal medicine 2013;28(9):1157-1164. Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. Journal of general internal medicine 2014;29(4):579-586. Harrison M, Collins CD. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis? infection control & hospital epidemiology 2015;36(3):265-272. Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS One 2019;14(4):e0214222. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. : Oxford university press; 2015. Weinstein MC, Russell LB, Gold MR, Siegel JE. Cost-effectiveness in health and medicine. : Oxford university press; 1996. Moreno Viscaya M, Mejia Mejia A, Castro Jaramillo HE. Manual Metodológico, Evaluación de Tecnologías en Salud. Manual Metodológico, Evaluación de Tecnologías en Salud Bogotá: Instituto de Evaluación Tecnológica en Salud-IETS; 2014. Soto J. Evaluación económica de medicamentos y tecnologías sanitarias. DOI 2012;10:978-984. Kernick DP. Introduction to health economics for the medical practitioner. Postgrad Med J 2003;79(929):147-150. Palmer S, Raftery J. Opportunity cost. BMJ 1999;318(7197):1551-1552. Byford S, Raftery J. Economics notes: types of economic evaluation. BMJ 1998;316:1529. Timmins N. Ministers, not NHS England, should decide on the affordability of cost-effective new treatments. The King’s Fund.Retrieved November 2017;9:2019. Briggs AH, O'Brien BJ. The death of cost‐minimization analysis? Health Econ 2001;10(2):179-184. Mogyorosy Z, Smith P. The main methodological issues in costing health care services: a literature review. Centre for Health Economics, University of York Working Papers 2005(007cherp). Marrero Araújo, Martha de la Caridad, García Fariñas A. Bases conceptuales y metodológicas para estimar el costo de las enfermedades neumocócicas en niños en el primer nivel de atención de salud. Revista Cubana de Salud Pública 2017;43:606-623. Walley T, Haycox A, Boland A. Farmacoeconomía. : Elsevier; 2005. Briggs A. Handling uncertainty in economic evaluation. BMJ 1999;319(7202):120. Gaitán Duarte HG, Feliciano Alfonso JE. Búsqueda, evaluación y síntesis de la evidencia de efectividad y seguridad en evaluaciones de tecnología: manual metodológico. Banco Interamericano de Desarrollo 2017. Faggion CM. Critical appraisal of AMSTAR: challenges, limitations, and potential solutions from the perspective of an assessor. BMC Medical Research Methodology 2015;15(1):1-5. Pieper D, Puljak L, González-Lorenzo M, Minozzi S. Minor differences were found between AMSTAR 2 and ROBIS in the assessment of systematic reviews including both randomized and nonrandomized studies. J Clin Epidemiol 2019;108:26-33. Torgerson DJ, Raftery J. Discounting. BMJ 1999;319(7214):914-915. Mar J, Antoñanzas F, Pradas R, Arrospide A. Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: una guía práctica. Gaceta Sanitaria 2010;24(3):209-214. Villalobos AP, Barrero LI, Rivera SM, Ovalle MV, Valera D. Vigilancia de infecciones asociadas a la atención en salud, resistencia bacteriana y consumo de antibióticos en hospitales de alta complejidad, Colombia, 2011. Biomédica 2014;34:67-80. Buitrago Gutiérrez G. Relación entre el consumo de antibióticos y la resistencia bacteriana en instituciones colombianas de tercer nivel de atención. Instituto de Investigaciones Clínicas 2009. Tang J, Gao D, Zou P. Comparison of serum PCT and CRP levels in patients infected by different pathogenic microorganisms: a systematic review and meta-analysis. Brazilian Journal of Medical and Biological Research 2018;51. Sotillo-Díaz JC, Bermejo-López E, García-Olivares P, Peral-Gutiérrez JA, Sancho-González M, Guerrero-Sanz JE. Role of plasma procalcitonin in the diagnosis of ventilator-associated pneumonia: systematic review and metaanalysis. Medicina Intensiva (English Edition) 2014;38(6):337-346. Ibrahim WH, Mushtaq K, Raza T, Kartha A, Saleh AO, Malik RA. Effects of procalcitonin-guided treatment on antibiotic use and need for mechanical ventilation in patients with acute asthma exacerbation: meta-analysis of randomized controlled trials. International Journal of Infectious Diseases 2017;65:75-80. Hey J, Thompson-Leduc P, Kirson NY, Zimmer L, Wilkins D, Rice B, et al. Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM) 2018;56(8):1200-1209. Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Périat P, et al. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC family practice 2005;6(1):1-8. Ogasawara T, Umezawa H, Naito Y, Takeuchi T, Kato S, Yano T, et al. Procalcitonin-guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake. Respiratory Investigation 2014;52(2):107-113. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302(10):1059-1066. Verduri A, Luppi F, D’Amico R, Balduzzi S, Vicini R, Liverani A, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PloS one 2015;10(3):e0118241. Arévalo LF, Bernal JD. Costos médicos directos en el tratamiento de neumonía nosocomial asociada a ventilación mecánica (NAVM) en pacientes adultos en Colombia. 2015. Annane D, Maxime V, Faller JP, Mezher C, Clec'h C, Martel P, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ open 2013;3(2):e002186. Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA internal medicine 2016;176(9):1266-1276. Bouadma L, Luyt C, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. The Lancet 2010;375(9713):463-474. Branche AR, Walsh EE, Vargas R, Hulbert B, Formica MA, Baran A, et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. J Infect Dis 2015;212(11):1692-1700. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. The Lancet 2004;363(9409):600-607. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. American journal of respiratory and critical care medicine 2006;174(1):84-93. Corti C, Fally M, Fabricius-Bjerre A, Mortensen K, Jensen BN, Andreassen HF, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. International Journal of Chronic Obstructive Pulmonary Disease 2016;11:1381. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. The Lancet Infectious Diseases 2016;16(7):819-827. Deliberato RO, Marra AR, Sanches PR, Martino MDV, dos Santos Ferreira, Carlos Eduardo, Pasternak J, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis 2013;76(3):266-271. Ding J, Chen Z, Feng K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. International journal of medical sciences 2013;10(7):903. Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical care 2009;13(3):1-7. Kristoffersen KB, Søgaard OS, Wejse C, Black FT, Greve T, Tarp B, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission—a randomized trial. Clinical Microbiology and Infection 2009;15(5):481-487. Layios N, Lambermont B, Canivet J, Morimont P, Preiser J, Garweg C, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 2012;40(8):2304-2309. Lima SSS, Nobre V, de Castro Romanelli, Roberta Maia, Clemente WT, da Silva Bittencourt, Henrique Neves, Melo ACM, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol 2016;95(7):1169-1176. Najafi A, Khodadadian A, Sanatkar M, Moharari RS, Etezadi F, Ahmadi A, et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. Acta Med Iran 2015:562-567. Nobre V, Harbarth S, Graf J, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American journal of respiratory and critical care medicine 2008;177(5):498-505. Schroeder S, Hochreiter M, Koehler T, Schweiger A, Bein B, Keck FS, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbeck's archives of surgery 2009;394(2):221-226. Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American journal of respiratory and critical care medicine 2014;190(10):1102-1110. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131(1):9-19. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. European Respiratory Journal 2009;34(6):1364-1375. Tang J, Long W, Yan L, Zhang Y, Xie J, Lu G, et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC infectious diseases 2013;13(1):1-8. Wang J, Zhang S, Li X, Zhang Y, Xu Z, Cao B. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. International Journal of Infectious Diseases 2016;48:40-45. van der Maas, Marloes E, Mantjes G, Steuten LM. Procalcitonin biomarker algorithm reduces antibiotic prescriptions, duration of therapy, and costs in chronic obstructive pulmonary disease: a comparison in the Netherlands, Germany, and the United Kingdom. Omics: a journal of integrative biology 2017;21(4):232-243. Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Official journal of the American College of Gastroenterology\| ACG 2021;116(6):1124-1147. Bradley-Ridout G, Nekolaichuk E, Jamieson T, Jones C, Morson N, Chuang R, et al. UpToDate versus DynaMed: a cross-sectional study comparing the speed and accuracy of two point-of-care information tools. Journal of the Medical Library Association: JMLA 2021;109(3):382. Li Z, Yuan X, Yu L, Wang B, Gao F, Ma J. Procalcitonin-guided antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease: An updated meta-analysis. Medicine (Baltimore) 2019 -08;98(32):e16775. Ni W, Bao J, Yang D, Xi W, Wang K, Xu Y, et al. Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis. Infect Dis (Lond) 2019 -09;51(9):639-650. Elyasi S, Khalili H, Hatamkhani S, Dashti-Khavidaki S. Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. Eur J Clin Pharmacol 2013 -04;69(4):747-754. Lisboa T, Salluh J, Povoa P. Do we need new trials of procalcitonin-guided antibiotic therapy? Critical Care 2018;22(17). Pugh R, Grant C, Cooke RPD, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015 -08-24(8):CD007577. Amour J, Birenbaum A, Langeron O, Le Manach Y, Bertrand M, Coriat P, et al. Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med 2008;36(4):1147-1154. Wussler D, Kozhuharov N, Tavares Oliveira M, Bossa A, Sabti Z, Nowak A, et al. Clinical Utility of Procalcitonin in the Diagnosis of Pneumonia. Clin Chem 2019 -12;65(12):1532-1542.
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv	Atribución-NoComercial-SinDerivadas 4.0 Internacional
dc.rights.uri.spa.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Atribución-NoComercial-SinDerivadas 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.extent.spa.fl_str_mv	xiii, 121 páginas
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.coverage.temporal.none.fl_str_mv	2019
dc.coverage.country.none.fl_str_mv	Colombia
dc.publisher.spa.fl_str_mv	Universidad Nacional de Colombia
dc.publisher.program.spa.fl_str_mv	Bogotá - Medicina - Maestría en Epidemiología Clínica
dc.publisher.faculty.spa.fl_str_mv	Facultad de Medicina
dc.publisher.place.spa.fl_str_mv	Bogotá, Colombia
dc.publisher.branch.spa.fl_str_mv	Universidad Nacional de Colombia - Sede Bogotá
institution	Universidad Nacional de Colombia
bitstream.url.fl_str_mv	https://repositorio.unal.edu.co/bitstream/unal/84577/1/license.txt https://repositorio.unal.edu.co/bitstream/unal/84577/2/80075835.2022.pdf https://repositorio.unal.edu.co/bitstream/unal/84577/3/80075835.2022.pdf.jpg
bitstream.checksum.fl_str_mv	eb34b1cf90b7e1103fc9dfd26be24b4a b8742166955550ae7ae610de5f356456 fcb1918d1dcf31c94e410fc1ba0c1025
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional Universidad Nacional de Colombia
repository.mail.fl_str_mv	repositorio_nal@unal.edu.co
_version_	1814089486697496576
spelling	Atribución-NoComercial-SinDerivadas 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Gaitan Duarte, Hernando Guillermo688532f1485f6001d8ea0f45f1e09340Medina Parra, Jorge Alexis302a896a9642474ef1048c84bcce1c112019Colombia2023-08-17T14:28:52Z2023-08-17T14:28:52Z2022https://repositorio.unal.edu.co/handle/unal/84577Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustraciones, diagramasResumen Introducción: La infección respiratoria aguda representa una alta carga de la enfermedad para las instituciones hospitalarias, esta patología se asocia a un alto consumo de antibióticos por su dificultad en el diagnóstico etiológico. La evidencia en Procalcitonina por otra parte, sugiere ser un biomarcador seguro y eficaz como guía para el tratamiento antibiótico en condiciones respiratorias agudas. Objetivo: Determinar si el uso de la procalcitonina como guía de la terapia antibiótica es Costo Efectiva en Infección respiratoria aguda en un hospital de referencia en Colombia para el año 2019. Metodología: Estudio integrativo, tipo Evaluación Económica, como fuente de efectividad se realizó una revisión sistemática de la literatura y como fuente de costos se realizó un costeo por caso tipo, con un análisis final mediante un modelo de simulación de Árbol de Decisión. Resultados: La procalcitonina como guía de la terapia antibiótica tiene una evidencia de moderada a alta en la literatura. Resulto más costosa (Costos Incrementales=$369,209) y más efectiva (Efectividad Incremental=0.06), para evitar un evento adverso atribuible al antibiótico comparado contra el manejo estándar de la infección respiratoria aguda. Con mejor perfil en el manejo del paciente en hospitalización general y mayor incertidumbre en los parámetros de costos. Conclusiones: La Procalcitonina tiene una probabilidad intermedia de ser costo efectiva en el escenario menos conservador, para evitar un evento atribuible al antibiótico. Se recomienda su uso personalizado, para optimizar su perfil de costo efectividad. (Texto tomado de la fuente)Abstract Introduction: Acute respiratory infection represents a high burden of disease for hospital institutions, this pathology is associated with high consumption of antibiotics due to its difficulty in etiological diagnosis. The evidence on Procalcitonin, on the other hand, suggests that it is a safe and effective biomarker to guide antibiotic treatment in acute respiratory conditions. Objective: To evaluate if the use of procalcitonin as a guide for antibiotic therapy is Cost Effective in acute respiratory infection in a reference hospital in Colombia for the year 2019. Methodology: Integrative study, Economic Evaluation, Cost effectiveness assessment. The source of effectiveness was obtained through a systematic review of the literature and the costs was obtained thought a costing by case type. A simulation analysis with a Decision Tree model was performed. Results: Procalcitonin as a guide for antibiotic therapy has moderate to high evidence in the literature and was more costly (Incremental Cost=$369,209) and more effective (Incremental Effectivity=0.06) in preventing an adverse event attributable to antibiotic therapy compared to standard management of acute respiratory infection. With a better profile in patient management in general hospitalization and greater uncertainty in cost parameters. Conclusions: Procalcitonin has an intermediate probability of being cost-effective in the least conservative scenario to avoid an event attributable to the antibiotic, is recommended to use it in a personalized mode rather than per protocol in all patients, in order to optimize its cost-effectiveness profile.MaestríaMagíster en Epidemiología Clínicaxiii, 121 páginasapplication/pdfUniversidad Nacional de ColombiaBogotá - Medicina - Maestría en Epidemiología ClínicaFacultad de MedicinaBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá610 - Medicina y salud::616 - EnfermedadesCosto d emedicamentosFármacos del sistema respiratorioDrug CostsRespiratory System AgentsAnálisis de costosCost analysisProcalcitoninaNeumoníaCosto EfectividadEvaluación de Tecnologías en SaludInfección Respiratoria AgudaProcalcitoninPneumoniaCost EffectivenessHealth Technology AssessmentAcute Respiratory InfectionEvaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad.Economic evaluation of procalcitonin as a guide to antibiotic therapy for acute respiratory infection in adults in a reference hospital in Colombia 2019. Cost-effectiveness analysis.Trabajo de grado - Maestríainfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/acceptedVersionTexthttp://purl.org/redcol/resource_type/TMMalo DC, Pulido PA. Infección Respiratoria Aguda Colombia 2017. Instituto Nacional de Salud 2018 Abril 20 de.World Health Organization. Pneumonia. 2021; Available at: https://www.who.int/news-room/fact-sheets/detail/pneumonia.Recomendaciones para el diagnóstico, tratamiento y prevención de la neumonía adquirida en la comunidad en adultos inmunocompetentes. Infectio 2013;17:1-38.DANE. Boletín Técnico Estadísticas Vitales. DANE 2016 30 de Marzo de.Montúfar FE, Rueda ZV, Correa LT, Ortega H, Ortega J, Segura A. Características y comportamiento de la Neumonía Adquirida en la Comunidad (NAC) en adultos mayores (≥ 65 años) hospitalizados en el Valle de Aburrá, Antioquia, Colombia. Infectio 2006(10):113.Hincapié C, Ascuntar J, León A, Jaimes F. Neumonía adquirida en la comunidad: comparación de tres puntuaciones de predicción de mortalidad en el servicio de urgencias. Colombia Médica 2021;52(4):e2044287.Fabian Bautista Peña. Perfil clínico, epidemiológico y microbiológico de los pacientes con neumonía en un hospital de Bogotá en el periodo de 2016-2019Universidad Nacional de Colombia; 2019.Pantoja-Chamorro F, Mazzillo-Vega L, Palacios-Barahona U. Análisis de la asociación entre procalcitonina y mortalidad por sepsis en menores de 18 años en una unidad de cuidados intensivos, Pasto-Colombia 2012-2014. Universidad y Salud 2018;20(1):64-71.González Rangel DM. Procalcitonina sérica como marcador de infección bacteriana comprobada por medio de cultivo en niños hospitalizados en la Fundación Hospital de la Misericordia (HOMI). Departamento de Pediatría 2014.Zaas AK, Garner BH, Tsalik EL, Burke T, Woods CW, Ginsburg GS. The current epidemiology and clinical decisions surrounding acute respiratory infections. Trends Mol Med 2014;20(10):579-588.Thapa S, Gokhale S, Sharma AL, Sapkota LB, Ansari S, Gautam R, et al. Burden of bacterial upper respiratory tract pathogens in school children of Nepal. BMJ open respiratory research 2017;4(1):e000203.Graham NM. The epidemiology of acute respiratory infections in children and adults: a global perspective. Epidemiol Rev 1990;12:149-178.Dasaraju PV, Liu C. Infections of the Respiratory System. 4th ed.: University of Texas Medical Branch at Galveston; 1996.Carroll KC, Adams LL. Lower Respiratory Tract Infections. Microbiol Spectr 2016 -08;4(4).Mahashur A. Management of lower respiratory tract infection in outpatient settings: Focus on clarithromycin. Lung India: Official Organ of Indian Chest Society 2018;35(2):143.Hopstaken RM. Lower respiratory tract infections unravelled. Ned Tijdschr Geneeskd 2019;163.Community-acquired pneumonia: the US perspective. Seminars in respiratory and critical care medicine: © Thieme Medical Publishers; 2009.Longo DL, Jameson JL, Kaspe D. Harrison's Principles of Internal Medicine: Volume 2. : Macgraw-Hill; 2011.Robinson NE, Furlow PW. Anatomy of the respiratory system. Equine respiratory medicine and surgery 2007:3-17.Robinson KM, Kolls JK, Alcorn JF. The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol 2015;34:59-67.Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. American journal of respiratory and critical care medicine 1999;160(2):397-405.Lower respiratory tract infection and pneumonia in the community. Seminars in respiratory infections; 1999.Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia?: Diagnosing pneumonia by history and physical examination. JAMA 1997;278(17):1440-1445.Protocolo de Vigilancia en Salud Pública, Infección Respiratoria Aguda. Instituto Nacional de Salud. Equipo Imunoprevenibles 2017.Ilg A, Moskowitz A, Konanki V, Patel PV, Chase M, Grossestreuer AV, et al. Performance of the CURB-65 score in predicting critical care interventions in patients admitted with community-acquired pneumonia. Ann Emerg Med 2019;74(1):60-68.Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243-250.Lim HF, Phua J, Mukhopadhyay A, Ngerng WJ, Chew MY, Sim TB, et al. IDSA/ATS minor criteria aid pre-intensive care unit resuscitation in severe community-acquired pneumonia. European Respiratory Journal 2014;43(3):852-862.Domínguez-Comesaña E, Ballinas-Miranda JR. Procalcitonin as a marker of intraabdominal infection. Cir Cir 2014;82(2):231-239.Henriquez-Camacho C, Losa J. Biomarkers for sepsis. BioMed research international 2014;2014.Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. The Journal of Clinical Endocrinology & Metabolism 1994;79(6):1605-1608.Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med 2013;28(3):285.Adib M, Bakhshiani Z, Navaei F, Fosoul FS, Fouladi S, Kazemzadeh H. Procalcitonin: a reliable marker for the diagnosis of neonatal sepsis. Iranian journal of basic medical sciences 2012;15(2):777.Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. The Lancet infectious diseases 2013;13(5):426-435.Wu M, Lin C, Huang S, Shih H, Wang C, Lee C, et al. Can procalcitonin tests aid in identifying bacterial infections associated with influenza pneumonia? A systematic review and meta‐analysis. Influenza and other respiratory viruses 2013;7(3):349-355.Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. European Respiratory Review 2017;26(143).Schuetz P, Wirz Y, Sager R, Christ‐Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews 2017(10).Smith KJ, Wateska A, Nowalk MP, Raymund M, Lee BY, Zimmerman RK, et al. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. Journal of general internal medicine 2013;28(9):1157-1164.Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. Journal of general internal medicine 2014;29(4):579-586.Harrison M, Collins CD. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis? infection control & hospital epidemiology 2015;36(3):265-272.Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS One 2019;14(4):e0214222.Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. : Oxford university press; 2015.Weinstein MC, Russell LB, Gold MR, Siegel JE. Cost-effectiveness in health and medicine. : Oxford university press; 1996.Moreno Viscaya M, Mejia Mejia A, Castro Jaramillo HE. Manual Metodológico, Evaluación de Tecnologías en Salud. Manual Metodológico, Evaluación de Tecnologías en Salud Bogotá: Instituto de Evaluación Tecnológica en Salud-IETS; 2014.Soto J. Evaluación económica de medicamentos y tecnologías sanitarias. DOI 2012;10:978-984.Kernick DP. Introduction to health economics for the medical practitioner. Postgrad Med J 2003;79(929):147-150.Palmer S, Raftery J. Opportunity cost. BMJ 1999;318(7197):1551-1552.Byford S, Raftery J. Economics notes: types of economic evaluation. BMJ 1998;316:1529.Timmins N. Ministers, not NHS England, should decide on the affordability of cost-effective new treatments. The King’s Fund.Retrieved November 2017;9:2019.Briggs AH, O'Brien BJ. The death of cost‐minimization analysis? Health Econ 2001;10(2):179-184.Mogyorosy Z, Smith P. The main methodological issues in costing health care services: a literature review. Centre for Health Economics, University of York Working Papers 2005(007cherp).Marrero Araújo, Martha de la Caridad, García Fariñas A. Bases conceptuales y metodológicas para estimar el costo de las enfermedades neumocócicas en niños en el primer nivel de atención de salud. Revista Cubana de Salud Pública 2017;43:606-623.Walley T, Haycox A, Boland A. Farmacoeconomía. : Elsevier; 2005.Briggs A. Handling uncertainty in economic evaluation. BMJ 1999;319(7202):120.Gaitán Duarte HG, Feliciano Alfonso JE. Búsqueda, evaluación y síntesis de la evidencia de efectividad y seguridad en evaluaciones de tecnología: manual metodológico. Banco Interamericano de Desarrollo 2017.Faggion CM. Critical appraisal of AMSTAR: challenges, limitations, and potential solutions from the perspective of an assessor. BMC Medical Research Methodology 2015;15(1):1-5.Pieper D, Puljak L, González-Lorenzo M, Minozzi S. Minor differences were found between AMSTAR 2 and ROBIS in the assessment of systematic reviews including both randomized and nonrandomized studies. J Clin Epidemiol 2019;108:26-33.Torgerson DJ, Raftery J. Discounting. BMJ 1999;319(7214):914-915.Mar J, Antoñanzas F, Pradas R, Arrospide A. Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: una guía práctica. Gaceta Sanitaria 2010;24(3):209-214.Villalobos AP, Barrero LI, Rivera SM, Ovalle MV, Valera D. Vigilancia de infecciones asociadas a la atención en salud, resistencia bacteriana y consumo de antibióticos en hospitales de alta complejidad, Colombia, 2011. Biomédica 2014;34:67-80.Buitrago Gutiérrez G. Relación entre el consumo de antibióticos y la resistencia bacteriana en instituciones colombianas de tercer nivel de atención. Instituto de Investigaciones Clínicas 2009.Tang J, Gao D, Zou P. Comparison of serum PCT and CRP levels in patients infected by different pathogenic microorganisms: a systematic review and meta-analysis. Brazilian Journal of Medical and Biological Research 2018;51.Sotillo-Díaz JC, Bermejo-López E, García-Olivares P, Peral-Gutiérrez JA, Sancho-González M, Guerrero-Sanz JE. Role of plasma procalcitonin in the diagnosis of ventilator-associated pneumonia: systematic review and metaanalysis. Medicina Intensiva (English Edition) 2014;38(6):337-346.Ibrahim WH, Mushtaq K, Raza T, Kartha A, Saleh AO, Malik RA. Effects of procalcitonin-guided treatment on antibiotic use and need for mechanical ventilation in patients with acute asthma exacerbation: meta-analysis of randomized controlled trials. International Journal of Infectious Diseases 2017;65:75-80.Hey J, Thompson-Leduc P, Kirson NY, Zimmer L, Wilkins D, Rice B, et al. Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM) 2018;56(8):1200-1209.Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Périat P, et al. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC family practice 2005;6(1):1-8.Ogasawara T, Umezawa H, Naito Y, Takeuchi T, Kato S, Yano T, et al. Procalcitonin-guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake. Respiratory Investigation 2014;52(2):107-113.Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302(10):1059-1066.Verduri A, Luppi F, D’Amico R, Balduzzi S, Vicini R, Liverani A, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PloS one 2015;10(3):e0118241.Arévalo LF, Bernal JD. Costos médicos directos en el tratamiento de neumonía nosocomial asociada a ventilación mecánica (NAVM) en pacientes adultos en Colombia. 2015.Annane D, Maxime V, Faller JP, Mezher C, Clec'h C, Martel P, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ open 2013;3(2):e002186.Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA internal medicine 2016;176(9):1266-1276.Bouadma L, Luyt C, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. The Lancet 2010;375(9713):463-474.Branche AR, Walsh EE, Vargas R, Hulbert B, Formica MA, Baran A, et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. J Infect Dis 2015;212(11):1692-1700.Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. The Lancet 2004;363(9409):600-607.Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. American journal of respiratory and critical care medicine 2006;174(1):84-93.Corti C, Fally M, Fabricius-Bjerre A, Mortensen K, Jensen BN, Andreassen HF, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. International Journal of Chronic Obstructive Pulmonary Disease 2016;11:1381.de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. The Lancet Infectious Diseases 2016;16(7):819-827.Deliberato RO, Marra AR, Sanches PR, Martino MDV, dos Santos Ferreira, Carlos Eduardo, Pasternak J, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis 2013;76(3):266-271.Ding J, Chen Z, Feng K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. International journal of medical sciences 2013;10(7):903.Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical care 2009;13(3):1-7.Kristoffersen KB, Søgaard OS, Wejse C, Black FT, Greve T, Tarp B, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission—a randomized trial. Clinical Microbiology and Infection 2009;15(5):481-487.Layios N, Lambermont B, Canivet J, Morimont P, Preiser J, Garweg C, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 2012;40(8):2304-2309.Lima SSS, Nobre V, de Castro Romanelli, Roberta Maia, Clemente WT, da Silva Bittencourt, Henrique Neves, Melo ACM, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol 2016;95(7):1169-1176.Najafi A, Khodadadian A, Sanatkar M, Moharari RS, Etezadi F, Ahmadi A, et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. Acta Med Iran 2015:562-567.Nobre V, Harbarth S, Graf J, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American journal of respiratory and critical care medicine 2008;177(5):498-505.Schroeder S, Hochreiter M, Koehler T, Schweiger A, Bein B, Keck FS, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbeck's archives of surgery 2009;394(2):221-226.Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American journal of respiratory and critical care medicine 2014;190(10):1102-1110.Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131(1):9-19.Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. European Respiratory Journal 2009;34(6):1364-1375.Tang J, Long W, Yan L, Zhang Y, Xie J, Lu G, et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC infectious diseases 2013;13(1):1-8.Wang J, Zhang S, Li X, Zhang Y, Xu Z, Cao B. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. International Journal of Infectious Diseases 2016;48:40-45.van der Maas, Marloes E, Mantjes G, Steuten LM. Procalcitonin biomarker algorithm reduces antibiotic prescriptions, duration of therapy, and costs in chronic obstructive pulmonary disease: a comparison in the Netherlands, Germany, and the United Kingdom. Omics: a journal of integrative biology 2017;21(4):232-243.Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Official journal of the American College of Gastroenterology\| ACG 2021;116(6):1124-1147.Bradley-Ridout G, Nekolaichuk E, Jamieson T, Jones C, Morson N, Chuang R, et al. UpToDate versus DynaMed: a cross-sectional study comparing the speed and accuracy of two point-of-care information tools. Journal of the Medical Library Association: JMLA 2021;109(3):382.Li Z, Yuan X, Yu L, Wang B, Gao F, Ma J. Procalcitonin-guided antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease: An updated meta-analysis. Medicine (Baltimore) 2019 -08;98(32):e16775.Ni W, Bao J, Yang D, Xi W, Wang K, Xu Y, et al. Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis. Infect Dis (Lond) 2019 -09;51(9):639-650.Elyasi S, Khalili H, Hatamkhani S, Dashti-Khavidaki S. Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. Eur J Clin Pharmacol 2013 -04;69(4):747-754.Lisboa T, Salluh J, Povoa P. Do we need new trials of procalcitonin-guided antibiotic therapy? Critical Care 2018;22(17).Pugh R, Grant C, Cooke RPD, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015 -08-24(8):CD007577.Amour J, Birenbaum A, Langeron O, Le Manach Y, Bertrand M, Coriat P, et al. Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med 2008;36(4):1147-1154.Wussler D, Kozhuharov N, Tavares Oliveira M, Bossa A, Sabti Z, Nowak A, et al. Clinical Utility of Procalcitonin in the Diagnosis of Pneumonia. Clin Chem 2019 -12;65(12):1532-1542.LICENSElicense.txtlicense.txttext/plain; charset=utf-85879https://repositorio.unal.edu.co/bitstream/unal/84577/1/license.txteb34b1cf90b7e1103fc9dfd26be24b4aMD51ORIGINAL80075835.2022.pdf80075835.2022.pdfTesis de Maestría en Epidemiología Clínicaapplication/pdf1797806https://repositorio.unal.edu.co/bitstream/unal/84577/2/80075835.2022.pdfb8742166955550ae7ae610de5f356456MD52THUMBNAIL80075835.2022.pdf.jpg80075835.2022.pdf.jpgGenerated Thumbnailimage/jpeg5906https://repositorio.unal.edu.co/bitstream/unal/84577/3/80075835.2022.pdf.jpgfcb1918d1dcf31c94e410fc1ba0c1025MD53unal/84577oai:repositorio.unal.edu.co:unal/845772023-08-17 23:04:14.071Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.coUEFSVEUgMS4gVMOJUk1JTk9TIERFIExBIExJQ0VOQ0lBIFBBUkEgUFVCTElDQUNJw5NOIERFIE9CUkFTIEVOIEVMIFJFUE9TSVRPUklPIElOU1RJVFVDSU9OQUwgVU5BTC4KCkxvcyBhdXRvcmVzIHkvbyB0aXR1bGFyZXMgZGUgbG9zIGRlcmVjaG9zIHBhdHJpbW9uaWFsZXMgZGUgYXV0b3IsIGNvbmZpZXJlbiBhIGxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhIHVuYSBsaWNlbmNpYSBubyBleGNsdXNpdmEsIGxpbWl0YWRhIHkgZ3JhdHVpdGEgc29icmUgbGEgb2JyYSBxdWUgc2UgaW50ZWdyYSBlbiBlbCBSZXBvc2l0b3JpbyBJbnN0aXR1Y2lvbmFsLCBiYWpvIGxvcyBzaWd1aWVudGVzIHTDqXJtaW5vczoKCgphKQlMb3MgYXV0b3JlcyB5L28gbG9zIHRpdHVsYXJlcyBkZSBsb3MgZGVyZWNob3MgcGF0cmltb25pYWxlcyBkZSBhdXRvciBzb2JyZSBsYSBvYnJhIGNvbmZpZXJlbiBhIGxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhIHVuYSBsaWNlbmNpYSBubyBleGNsdXNpdmEgcGFyYSByZWFsaXphciBsb3Mgc2lndWllbnRlcyBhY3RvcyBzb2JyZSBsYSBvYnJhOiBpKSByZXByb2R1Y2lyIGxhIG9icmEgZGUgbWFuZXJhIGRpZ2l0YWwsIHBlcm1hbmVudGUgbyB0ZW1wb3JhbCwgaW5jbHV5ZW5kbyBlbCBhbG1hY2VuYW1pZW50byBlbGVjdHLDs25pY28sIGFzw60gY29tbyBjb252ZXJ0aXIgZWwgZG9jdW1lbnRvIGVuIGVsIGN1YWwgc2UgZW5jdWVudHJhIGNvbnRlbmlkYSBsYSBvYnJhIGEgY3VhbHF1aWVyIG1lZGlvIG8gZm9ybWF0byBleGlzdGVudGUgYSBsYSBmZWNoYSBkZSBsYSBzdXNjcmlwY2nDs24gZGUgbGEgcHJlc2VudGUgbGljZW5jaWEsIHkgaWkpIGNvbXVuaWNhciBhbCBww7pibGljbyBsYSBvYnJhIHBvciBjdWFscXVpZXIgbWVkaW8gbyBwcm9jZWRpbWllbnRvLCBlbiBtZWRpb3MgYWzDoW1icmljb3MgbyBpbmFsw6FtYnJpY29zLCBpbmNsdXllbmRvIGxhIHB1ZXN0YSBhIGRpc3Bvc2ljacOzbiBlbiBhY2Nlc28gYWJpZXJ0by4gQWRpY2lvbmFsIGEgbG8gYW50ZXJpb3IsIGVsIGF1dG9yIHkvbyB0aXR1bGFyIGF1dG9yaXphIGEgbGEgVW5pdmVyc2lkYWQgTmFjaW9uYWwgZGUgQ29sb21iaWEgcGFyYSBxdWUsIGVuIGxhIHJlcHJvZHVjY2nDs24geSBjb211bmljYWNpw7NuIGFsIHDDumJsaWNvIHF1ZSBsYSBVbml2ZXJzaWRhZCByZWFsaWNlIHNvYnJlIGxhIG9icmEsIGhhZ2EgbWVuY2nDs24gZGUgbWFuZXJhIGV4cHJlc2EgYWwgdGlwbyBkZSBsaWNlbmNpYSBDcmVhdGl2ZSBDb21tb25zIGJham8gbGEgY3VhbCBlbCBhdXRvciB5L28gdGl0dWxhciBkZXNlYSBvZnJlY2VyIHN1IG9icmEgYSBsb3MgdGVyY2Vyb3MgcXVlIGFjY2VkYW4gYSBkaWNoYSBvYnJhIGEgdHJhdsOpcyBkZWwgUmVwb3NpdG9yaW8gSW5zdGl0dWNpb25hbCwgY3VhbmRvIHNlYSBlbCBjYXNvLiBFbCBhdXRvciB5L28gdGl0dWxhciBkZSBsb3MgZGVyZWNob3MgcGF0cmltb25pYWxlcyBkZSBhdXRvciBwb2Ryw6EgZGFyIHBvciB0ZXJtaW5hZGEgbGEgcHJlc2VudGUgbGljZW5jaWEgbWVkaWFudGUgc29saWNpdHVkIGVsZXZhZGEgYSBsYSBEaXJlY2Npw7NuIE5hY2lvbmFsIGRlIEJpYmxpb3RlY2FzIGRlIGxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhLiAKCmIpIAlMb3MgYXV0b3JlcyB5L28gdGl0dWxhcmVzIGRlIGxvcyBkZXJlY2hvcyBwYXRyaW1vbmlhbGVzIGRlIGF1dG9yIHNvYnJlIGxhIG9icmEgY29uZmllcmVuIGxhIGxpY2VuY2lhIHNlw7FhbGFkYSBlbiBlbCBsaXRlcmFsIGEpIGRlbCBwcmVzZW50ZSBkb2N1bWVudG8gcG9yIGVsIHRpZW1wbyBkZSBwcm90ZWNjacOzbiBkZSBsYSBvYnJhIGVuIHRvZG9zIGxvcyBwYcOtc2VzIGRlbCBtdW5kbywgZXN0byBlcywgc2luIGxpbWl0YWNpw7NuIHRlcnJpdG9yaWFsIGFsZ3VuYS4KCmMpCUxvcyBhdXRvcmVzIHkvbyB0aXR1bGFyZXMgZGUgZGVyZWNob3MgcGF0cmltb25pYWxlcyBkZSBhdXRvciBtYW5pZmllc3RhbiBlc3RhciBkZSBhY3VlcmRvIGNvbiBxdWUgbGEgcHJlc2VudGUgbGljZW5jaWEgc2Ugb3RvcmdhIGEgdMOtdHVsbyBncmF0dWl0bywgcG9yIGxvIHRhbnRvLCByZW51bmNpYW4gYSByZWNpYmlyIGN1YWxxdWllciByZXRyaWJ1Y2nDs24gZWNvbsOzbWljYSBvIGVtb2x1bWVudG8gYWxndW5vIHBvciBsYSBwdWJsaWNhY2nDs24sIGRpc3RyaWJ1Y2nDs24sIGNvbXVuaWNhY2nDs24gcMO6YmxpY2EgeSBjdWFscXVpZXIgb3RybyB1c28gcXVlIHNlIGhhZ2EgZW4gbG9zIHTDqXJtaW5vcyBkZSBsYSBwcmVzZW50ZSBsaWNlbmNpYSB5IGRlIGxhIGxpY2VuY2lhIENyZWF0aXZlIENvbW1vbnMgY29uIHF1ZSBzZSBwdWJsaWNhLgoKZCkJUXVpZW5lcyBmaXJtYW4gZWwgcHJlc2VudGUgZG9jdW1lbnRvIGRlY2xhcmFuIHF1ZSBwYXJhIGxhIGNyZWFjacOzbiBkZSBsYSBvYnJhLCBubyBzZSBoYW4gdnVsbmVyYWRvIGxvcyBkZXJlY2hvcyBkZSBwcm9waWVkYWQgaW50ZWxlY3R1YWwsIGluZHVzdHJpYWwsIG1vcmFsZXMgeSBwYXRyaW1vbmlhbGVzIGRlIHRlcmNlcm9zLiBEZSBvdHJhIHBhcnRlLCAgcmVjb25vY2VuIHF1ZSBsYSBVbml2ZXJzaWRhZCBOYWNpb25hbCBkZSBDb2xvbWJpYSBhY3TDumEgY29tbyB1biB0ZXJjZXJvIGRlIGJ1ZW5hIGZlIHkgc2UgZW5jdWVudHJhIGV4ZW50YSBkZSBjdWxwYSBlbiBjYXNvIGRlIHByZXNlbnRhcnNlIGFsZ8O6biB0aXBvIGRlIHJlY2xhbWFjacOzbiBlbiBtYXRlcmlhIGRlIGRlcmVjaG9zIGRlIGF1dG9yIG8gcHJvcGllZGFkIGludGVsZWN0dWFsIGVuIGdlbmVyYWwuIFBvciBsbyB0YW50bywgbG9zIGZpcm1hbnRlcyAgYWNlcHRhbiBxdWUgY29tbyB0aXR1bGFyZXMgw7puaWNvcyBkZSBsb3MgZGVyZWNob3MgcGF0cmltb25pYWxlcyBkZSBhdXRvciwgYXN1bWlyw6FuIHRvZGEgbGEgcmVzcG9uc2FiaWxpZGFkIGNpdmlsLCBhZG1pbmlzdHJhdGl2YSB5L28gcGVuYWwgcXVlIHB1ZWRhIGRlcml2YXJzZSBkZSBsYSBwdWJsaWNhY2nDs24gZGUgbGEgb2JyYS4gIAoKZikJQXV0b3JpemFuIGEgbGEgVW5pdmVyc2lkYWQgTmFjaW9uYWwgZGUgQ29sb21iaWEgaW5jbHVpciBsYSBvYnJhIGVuIGxvcyBhZ3JlZ2Fkb3JlcyBkZSBjb250ZW5pZG9zLCBidXNjYWRvcmVzIGFjYWTDqW1pY29zLCBtZXRhYnVzY2Fkb3Jlcywgw61uZGljZXMgeSBkZW3DoXMgbWVkaW9zIHF1ZSBzZSBlc3RpbWVuIG5lY2VzYXJpb3MgcGFyYSBwcm9tb3ZlciBlbCBhY2Nlc28geSBjb25zdWx0YSBkZSBsYSBtaXNtYS4gCgpnKQlFbiBlbCBjYXNvIGRlIGxhcyB0ZXNpcyBjcmVhZGFzIHBhcmEgb3B0YXIgZG9ibGUgdGl0dWxhY2nDs24sIGxvcyBmaXJtYW50ZXMgc2Vyw6FuIGxvcyByZXNwb25zYWJsZXMgZGUgY29tdW5pY2FyIGEgbGFzIGluc3RpdHVjaW9uZXMgbmFjaW9uYWxlcyBvIGV4dHJhbmplcmFzIGVuIGNvbnZlbmlvLCBsYXMgbGljZW5jaWFzIGRlIGFjY2VzbyBhYmllcnRvIENyZWF0aXZlIENvbW1vbnMgeSBhdXRvcml6YWNpb25lcyBhc2lnbmFkYXMgYSBzdSBvYnJhIHBhcmEgbGEgcHVibGljYWNpw7NuIGVuIGVsIFJlcG9zaXRvcmlvIEluc3RpdHVjaW9uYWwgVU5BTCBkZSBhY3VlcmRvIGNvbiBsYXMgZGlyZWN0cmljZXMgZGUgbGEgUG9sw610aWNhIEdlbmVyYWwgZGUgbGEgQmlibGlvdGVjYSBEaWdpdGFsLgoKCmgpCVNlIGF1dG9yaXphIGEgbGEgVW5pdmVyc2lkYWQgTmFjaW9uYWwgZGUgQ29sb21iaWEgY29tbyByZXNwb25zYWJsZSBkZWwgdHJhdGFtaWVudG8gZGUgZGF0b3MgcGVyc29uYWxlcywgZGUgYWN1ZXJkbyBjb24gbGEgbGV5IDE1ODEgZGUgMjAxMiBlbnRlbmRpZW5kbyBxdWUgc2UgZW5jdWVudHJhbiBiYWpvIG1lZGlkYXMgcXVlIGdhcmFudGl6YW4gbGEgc2VndXJpZGFkLCBjb25maWRlbmNpYWxpZGFkIGUgaW50ZWdyaWRhZCwgeSBzdSB0cmF0YW1pZW50byB0aWVuZSB1bmEgZmluYWxpZGFkIGhpc3TDs3JpY2EsIGVzdGFkw61zdGljYSBvIGNpZW50w61maWNhIHNlZ8O6biBsbyBkaXNwdWVzdG8gZW4gbGEgUG9sw610aWNhIGRlIFRyYXRhbWllbnRvIGRlIERhdG9zIFBlcnNvbmFsZXMuCgoKClBBUlRFIDIuIEFVVE9SSVpBQ0nDk04gUEFSQSBQVUJMSUNBUiBZIFBFUk1JVElSIExBIENPTlNVTFRBIFkgVVNPIERFIE9CUkFTIEVOIEVMIFJFUE9TSVRPUklPIElOU1RJVFVDSU9OQUwgVU5BTC4KClNlIGF1dG9yaXphIGxhIHB1YmxpY2FjacOzbiBlbGVjdHLDs25pY2EsIGNvbnN1bHRhIHkgdXNvIGRlIGxhIG9icmEgcG9yIHBhcnRlIGRlIGxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhIHkgZGUgc3VzIHVzdWFyaW9zIGRlIGxhIHNpZ3VpZW50ZSBtYW5lcmE6CgphLglDb25jZWRvIGxpY2VuY2lhIGVuIGxvcyB0w6lybWlub3Mgc2XDsWFsYWRvcyBlbiBsYSBwYXJ0ZSAxIGRlbCBwcmVzZW50ZSBkb2N1bWVudG8sIGNvbiBlbCBvYmpldGl2byBkZSBxdWUgbGEgb2JyYSBlbnRyZWdhZGEgc2VhIHB1YmxpY2FkYSBlbiBlbCBSZXBvc2l0b3JpbyBJbnN0aXR1Y2lvbmFsIGRlIGxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhIHkgcHVlc3RhIGEgZGlzcG9zaWNpw7NuIGVuIGFjY2VzbyBhYmllcnRvIHBhcmEgc3UgY29uc3VsdGEgcG9yIGxvcyB1c3VhcmlvcyBkZSBsYSBVbml2ZXJzaWRhZCBOYWNpb25hbCBkZSBDb2xvbWJpYSAgYSB0cmF2w6lzIGRlIGludGVybmV0LgoKCgpQQVJURSAzIEFVVE9SSVpBQ0nDk04gREUgVFJBVEFNSUVOVE8gREUgREFUT1MgUEVSU09OQUxFUy4KCkxhIFVuaXZlcnNpZGFkIE5hY2lvbmFsIGRlIENvbG9tYmlhLCBjb21vIHJlc3BvbnNhYmxlIGRlbCBUcmF0YW1pZW50byBkZSBEYXRvcyBQZXJzb25hbGVzLCBpbmZvcm1hIHF1ZSBsb3MgZGF0b3MgZGUgY2Fyw6FjdGVyIHBlcnNvbmFsIHJlY29sZWN0YWRvcyBtZWRpYW50ZSBlc3RlIGZvcm11bGFyaW8sIHNlIGVuY3VlbnRyYW4gYmFqbyBtZWRpZGFzIHF1ZSBnYXJhbnRpemFuIGxhIHNlZ3VyaWRhZCwgY29uZmlkZW5jaWFsaWRhZCBlIGludGVncmlkYWQgeSBzdSB0cmF0YW1pZW50byBzZSByZWFsaXphIGRlIGFjdWVyZG8gYWwgY3VtcGxpbWllbnRvIG5vcm1hdGl2byBkZSBsYSBMZXkgMTU4MSBkZSAyMDEyIHkgZGUgbGEgUG9sw610aWNhIGRlIFRyYXRhbWllbnRvIGRlIERhdG9zIFBlcnNvbmFsZXMgZGUgbGEgVW5pdmVyc2lkYWQgTmFjaW9uYWwgZGUgQ29sb21iaWEuIFB1ZWRlIGVqZXJjZXIgc3VzIGRlcmVjaG9zIGNvbW8gdGl0dWxhciBhIGNvbm9jZXIsIGFjdHVhbGl6YXIsIHJlY3RpZmljYXIgeSByZXZvY2FyIGxhcyBhdXRvcml6YWNpb25lcyBkYWRhcyBhIGxhcyBmaW5hbGlkYWRlcyBhcGxpY2FibGVzIGEgdHJhdsOpcyBkZSBsb3MgY2FuYWxlcyBkaXNwdWVzdG9zIHkgZGlzcG9uaWJsZXMgZW4gd3d3LnVuYWwuZWR1LmNvIG8gZS1tYWlsOiBwcm90ZWNkYXRvc19uYUB1bmFsLmVkdS5jbyIKClRlbmllbmRvIGVuIGN1ZW50YSBsbyBhbnRlcmlvciwgYXV0b3Jpem8gZGUgbWFuZXJhIHZvbHVudGFyaWEsIHByZXZpYSwgZXhwbMOtY2l0YSwgaW5mb3JtYWRhIGUgaW5lcXXDrXZvY2EgYSBsYSBVbml2ZXJzaWRhZCBOYWNpb25hbCBkZSBDb2xvbWJpYSBhIHRyYXRhciBsb3MgZGF0b3MgcGVyc29uYWxlcyBkZSBhY3VlcmRvIGNvbiBsYXMgZmluYWxpZGFkZXMgZXNwZWPDrWZpY2FzIHBhcmEgZWwgZGVzYXJyb2xsbyB5IGVqZXJjaWNpbyBkZSBsYXMgZnVuY2lvbmVzIG1pc2lvbmFsZXMgZGUgZG9jZW5jaWEsIGludmVzdGlnYWNpw7NuIHkgZXh0ZW5zacOzbiwgYXPDrSBjb21vIGxhcyByZWxhY2lvbmVzIGFjYWTDqW1pY2FzLCBsYWJvcmFsZXMsIGNvbnRyYWN0dWFsZXMgeSB0b2RhcyBsYXMgZGVtw6FzIHJlbGFjaW9uYWRhcyBjb24gZWwgb2JqZXRvIHNvY2lhbCBkZSBsYSBVbml2ZXJzaWRhZC4gCgo=

Evaluación económica de la procalcitonina como guía de la terapia antibiótica para infección respiratoria aguda en adultos en un hospital de referencia en Colombia 2019. Análisis de costo efectividad.

Publicaciones similares